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Abstract
Background: The role of integrin signaling in mucosal inflammation is presently unknown. Hence, we aimed to
investigate the role of epithelial-derived integrin-linked kinase (ILK), a critical integrin signaling intermediary
molecule, in colonic inflammation.
Methods: Conditional intestinal epithelial cell ILK knockout mice were used for assessment of acute and chronic
dextran sodium sulfate (DSS) -induced colitis. Disease activity was scored using standard histological scoring,
mucosal cytokines were measured using ELISA, chemokines were determined using reverse-transcription
polymerase chain reaction, as well as Q-PCR, and intracellular cytokine staining performed using FACS analysis.
Results: In both acute and chronic DSS-induced colitis, compared to wild-type mice, ILK-ko mice exhibit less
weight loss, and have reduced inflammatory scores. In an in vitro model system using HCT116 cells, we
demonstrate that si-RNA mediated down-regulation of ILK results in a reduction in monocyte chemoattractant
protein 1 (MCP1, CCL2) chemokine expression. A reduction in CCL2 levels is also observed in the tissue lysates of
chronically inflamed colons from ILK-ko mice. Examination of mesenteric lymph node lymphocytes from ILK-ko
mice reveals that there is a reduction in the levels of IFN gamma using intracellular staining, together with an
increase in Foxp3+ T regulatory cells. Immunohistochemistry demonstrates that reduced fibronectin expression
characterizes the inflammatory lesions within the colons of ILK-ko mice. Intriguingly, we demonstrate that
fibronectin is directly capable of downregulating T regulatory cell development.
Conclusions: Collectively, the data indicate for the first time that ILK plays a pro-inflammatory role in intestinal
inflammation, through effects on chemokine expression, the extracellular matrix and immune tolerance.
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Background
Inflammatory bowel diseases are chronic disorders that
commonly affect individuals in the second to third dec-
ades of life. They are relatively common in the northern
hemisphere, and are also being increasingly recognized
in the developing world. A number of different genetic
mutations are associated with these diseases, and typi-
cally result in a dysregulated immune response to the
bacteria residing within the host gut [1,2]. The inflam-
matory response in IBD is characterized by an influx of
lymphocytes, monocytes and polymorphonuclear leuko-
cytes, which can all mediate chronic tissue damage.
Tumor necrosis factor alpha (TNFa) appears to be a
key factor in this process, as neutralization of this criti-
cal cytokine is highly efficacious in treating both Crohn’s
disease and ulcerative colitis [3,4].
Integrin-linked kinase (ILK) is an adapter protein that
links the extracellular matrix with the cell interior
through its interactions with the cytoplasmic tails of cer-
tain integrins. ILK plays a critical role in development,
as its knockdown results in failure of implantation of
the trophoblast. When ILK is deleted in specific tissues,
processes such as cardiac development; angiogenesis;
cartilage growth; skin growth; gut development and T-
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important role in cancer since it has oncogenic proper-
ties when overexpressed in cancer cell lines, and high
ILK expression in a variety of malignancies is associated
with a negative prognosis [6]. There is controversy sur-
rounding its ability to regulate the activity of protein
kinase B/Akt, but recent findings indicate that ILK acts
in concert with other molecules such as Pinch and Ric-
tor to achieve this effect [7,8].
There is scant data as yet on the role of ILK in
inflammation. Although T cell-specific deletion of ILK
did not establish a role in T cell proliferation, impaired
migration was described [9]. We have previously
observed that mice with a conditional epithelial cell
knockout of ILK develop smaller tumors, in response to
chronic inflammation associated with exposure to azox-
ymethane and dextran sodium sulfate administration
[10] suggesting that ILK may regulate inflammation. In
order to investigate this hypothesis we investigated the
role of epithelial cell-specific expression of ILK in acute
and chronic models of colitis. We report that ILK-ko
mice are significantly protected from colitis; protection
from disease is associated with altered expression of the
chemokine, CCL2, and fibronectin. Moreover, ILK-ko
mice have increased numbers of mucosal Tregs, consis-
tent with the finding that fibronectin can directly impact
on T regulatory cell development in vitro.
Methods
Materials
Anti-FoxP3 antibody was obtained from eBiosciences
(San Diego, CA); anti-fibronectin antibody from Abcam
( C a m b r i d g e ,M A ) ;a n t i - a l p h a 5 integrin antibody, alpha
5 integrin si-RNA, and ILK antibody from Santa Cruz
(Santa Cruz, CA); anti-CD3, anti-CD28 antibody from
BD Biosciences. ELISA kits for TNFa,I F N g, IL-12p40,
CCL2 were obtained from BD Biosciences (Mississauga,
ON). QLT0267 was kindly provided by QLT Inc, Van-
couver, BC, Canada. Horse-radish peroxidase conjugated
secondary antibodies were obtained through Calbiochem
(San Diego, CA). EGTA, EDTA, MOPS, PMSF, sodium
orthovanadate, leupeptin, aprotinin, benzamidine, dithio-
threitol and b-glycerolphosphate, were purchased from
Sigma.
Animal handling, processing, colitis induction and
analysis
Mice on an FVB (Friend virus B-type) background were
used for all the experimental work in this project. All
animals were kept in conventional housing in the animal
care facility at Jack Bell Research Centre. They were fed
chow ad libitum and had liberal access to drinking
water. All experiments were approved by the UBC Ani-
mal Ethics Committee (A05-1580). Colonic epithelial
cell specific inactivation of ILK was achieved by crossing
t h eF a b p- C r em i c ew i t ht h eI L K
flox/flox animals. The
resulting offspring were then backcrossed with the
homozygote floxed mice to generate the genotype: ILK-
flox/flox,Cre. Genotyping for Cre and ILK were carried
out as previously described [10]. Briefly, tail DNA was
obtained and the following primers used to detect Cre
expression: 5’-CCTGGAAAATGCTTCTGTCCG-3’ and
5’-CAGGGTGTTATAACAATCCC-3’.I L Kg e n o t y p e
was monitored using: 5’-CCAGGTGGCAGAGG-
TAAGTA-3’ and 5’-CAAGAAATAAGGTGAGCTTCA-
GAA-3’.
Acute and chronic colitis were induced using pre-
viously well-described methods [11] in 10 week old mice
of mixed gender. In the acute colitis model mice were
given 3.5% DSS in their drinking water for 1 week and
then terminated after 1 more week (ie at 12 weeks). In
the chronic colitis model, mice were started on the first
of three cycles of 5 days of 2.5% DSS given in the drink-
ing water followed by 1 week of normal tap water. Mice
were monitored daily for illness behaviour, weight
recording and sacrificed on day 36 (ie at just over 15
weeks of age). Their colons were examined for macro-
scopic and H& E for microscopic disease activity as pre-
viously described [12]. After removal, the colons were
fixed in 10% buffered formalin for immunohistochemis-
try, protein lysates were prepared for western analysis
and ELISA. Mesenteric lymph nodes and spleens were
removed, and lymphocytes harvested for intracellular
cytokine staining for FoxP3 and IFNg as described below.
SDS-Polyacrylamide Gel Electrophoresis
Colonic tissue or cultured cells were homogenized in buf-
fer containing 20 mM MOPS, 150 mM NaCl, 50 mM b-
glycerophosphate, 5 mM EGTA, 50 mM NaF, 1 mM DTT,
1 mM sodium vanadate, 0.5% NP40 and 1 mM PMSF.
After sonicating for 15 s (x 2) and centrifuging at 14,000
RPM for 15 min, the protein concentration in the superna-
tant was determined by the Bradford assay (Bio-Rad, Mis-
sissauga, Ont). 25 ug of protein from each sample was
resolved using 10% SDS-PAGE before transferring to nitro-
cellulose membranes (Bio-Rad). The blots were blocked in
5% skim milk in TBST (20 mM Tris-HCl pH 7.4, 250 mM
NaCl, 0.05% Tween-20) for 1 h before probing for 2 h
using the appropriate primary antibody. The blots were
washed with TBST for 10 min three times, before being
incubated with the appropriate secondary antibody for 1 h.
Following 3 further washes in TBST, they were developed
using the enhanced chemiluminescence detection system
(ECL, Amersham, Montreal, Quebec).
Immunohistochemistry
Paraffin-embedded colonic tissue samples were de-
waxed in xylene twice for 5 min, rehydrated in a series
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endogenous peroxidase was blocked with 0.3% hydrogen
peroxide followed by antigen retrieval by microwaving
sections in citrate buffer pH 6.0 (10 mM Na citrate).
Following antigen retrieval, the sections were washed
three times with PBS, blocked in 1% BSA for 1 h, and
then stained using the Vectastain ABC kit (Vector
laboratories, Burlingame, CA) mentioned below accord-
ing to manufacturer’s recommendations but with the
following modifications. Sections were incubated with
the following primary antibodies at 4°C overnight: ILK
(1:100, Cell Signaling, Pickering, Ontario), fibronectin
( 1 : 2 0 0 ,A b c a m ,C a m b r i d g e ,M A ) ,a n t i - F o x p 3( 1 : 1 0 0 ,
eBiosciences, San Diego, CA), anti-CD3 (1:100, Dako
Canada Inc., Mississauga, ON). Following incubation,
the sections were rinsed three consecutive times with
PBS and then incubated with the appropriate biotiny-
lated secondary antibody for 1 h followed by incubation
with peroxidase-labelled streptavidin. Nova -red and
DAB were used as the chromagens, and the sections
were counterstained with haematoxylin. Three blinded
observers independently examined all stained sections.
For detection of Th17 cells by immunofluorescence,
the slides were processed as for IHC and the following
antibodies were used: DAPI and IL-17A (eBio 17B7).
Sections were stained with Vectastain ABC elite kit and
biotinylated ant-rabbit for DAPI, or eFluor650 Nano-
crystal conjugation kit, cat no. 88-7072-98 antibody, and
Avidin D-FITC (or Avidin-Texas Red) used for immu-
nofluorescence (Vector laboratories, CA, USA). Each
section had its own control using the secondary anti-
body only. Pre-immune serum was initially used to
ensure specificity of the signal with each of the
antibodies.
Q-PCR
1 ug of RNA, obtained using Trizol from HCT116 cells,
was reverse transcribed using random hexamers (Per-
kin-Elmer Applied Biosystems, Branchburg, NJ) and 20
units of Moloney murine leukemia virus reverse tran-
scriptase M-MLV (Invitrogene) in 20 μlo ft o t a lv o l u m e
at 25°C for 10 min and at 37°C for 60 minutes. The
resulting first-strand complementary DNA (cDNA) was
used as template for the real-time quantitative-PCR.
The Applied Biosystems 5700 Sequence Detection Sys-
tem (Perkin-Elmer Applied Biosystems, Foster City, CA)
was used for real time monitoring of PCR amplification
of cDNA using the SYBRO Green Universal PCR Master
Mix protocol. Amplification of the following cDNAs was
performed using the primers listed:
CCL2: F: CTCTGCCGCCCTTCTGTG; R: TGCATCT
GGCTGAGCGAG
CXCL-8: F: GGCACAAACTTTCAGAGACAG; R:
ACACAGAGCTGCAGAAATCAGG
IBa: F: TTGGGTGCTGATGTCAATGC; R: AGGT
CCACTGCGAGGTGAAG
Relative quantification of gene expression was per-
formed using Beta-Actin as a control. Beta-Actin cDNA
was amplified separately on a duplicate set of samples
using standard primers from AB Applied Biosystems.
The comparative Ct (cycle threshold) method was used
for relative quantification of gene of interest mRNA.
Statistical significance was determined by ANOVA model.
The CT value is defined as the cycle number in which the
detected fluorescence exceeds the threshold value.
Fold difference = 2− CT1(gene of interest)−C
T1(Beta - Actin)|−|CT2(gene of interest - C)T2(Beta - Actin)||
Where CT1(gene of interest) and CT1(Beta-Actin)
represent the CT values for the treated samples, respec-
tively. CT2(gene of interest) and CT2(Beta-Actin) repre-
sent the CT values for the untreated samples,
respectively.
Cell Culture
HCT 116 cells were a kind gift of Bert Vogelstein (Johns
Hopkins, Baltimore, Maryland) and were cultured in
McCoys 5A Medium (Gibco, Burlington, Ontario) con-
taining 10% heat inactivated fetal bovine serum (FBS)
(Hyclone, Logan, Utah). Protein lysates were obtained
using homogenization buffer as described above.
Semiquantitative RT-PCR
1 ug of RNA, obtained using Trizol from HCT 116 cells
(or murine colon), was reverse transcribed using random
hexamers (Perkin-Elmer Applied Biosystems, Branch-
burg, NJ) and 20 units of Moloney murine leukemia
virus reverse transcriptase M-MLV (Invitrogene) in 20
μl of total volume at 25°C for 10 min and at 37°C for 60
min. The resulting first-strand complementary DNA
(cDNA) was used as template for the semi-quantitative-
PCR. Amplification of the following cDNAs was per-
formed using the primers listed: ILK(F): TTTTCACT-
CAGTGCCGGGAGG; (R): GTCCCTTGGCTTTGTCC
ACAG; CCL2 (F):ATGCAGGTCCCTGTCATGCT
TCTG; (R):CTAGTTCACTGTCACACTGGTCACTCC;
b-actin(F):AGAGGGAAATCGTGCGTGAC; (R):CAA-
TAGTGATGACCTGGCGGT. Relative quantification of
gene expression was performed using densitometry and
beta-actin as a control.
Si-RNA-mediated knockdown of ILK
This was performed as described previously [13] using a
21-mer to transfect HCT116 cells, grown to 60% con-
fluency, using Silentfect (Biorad). Two separate ILK
si-RNA and control (scrambled) sequences were
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Santa Cruz Biotechnology Corporation Inc (Santa Cruz,
Ca). Gene knockdown was confirmed using western blot-
ting and Q-PCR.
Determination of regulatory T cell numbers and
intracellular cytokine staining
To quantify Tregs and IFN-g production ex vivo, mesen-
teric lymph nodes were collected, and stimulated with
with phorbol myristate acetate (25 ng/ml) and ionomycin
(1 mg/ml) for 6 h in the presence of brefeldin A (10 mg/
ml) during the final 4 h. Cells were fixed and permeabi-
lised using FOXP3-specific kit reagents (e-biosciences)
and stained with anti-IFN-g-PECy-7 (XMG1.2), anti-TNF-
a-PE (JES5-16E3) or anti-IL-17-APC (17B7) (e-Bios-
ciences). All samples were read on a BD FACS Canto and
analyzed with FCS Express V3 (De Novo Software). To
assess Treg development in vitro, T cells were purified
and cultured in SFEM medium (StemCell Technologies),
supplemented with 10 mM HEPES, 2 mM glutamine, 1
mM sodium pyruvate, 1 mM MEM non-essential amino
acid solution and 100 U/ml each of Penicillin G and strep-
tomycin. Flat-bottom plates were coated with aCD3 (10
mg/ml, 2C11) and serial dilutions of the indicated concen-
tration of fibronectin (Sigma). Tregs were differentiated
from CD4
+CD25
- T cells in the absence or presence of
soluble CD28 (1 mg/ml, 37.51), rhIL-2 (100 U/ml, Chiron)
and rhTGF-b (10 ng/ml, R&D systems) as indicated.
Statistical analysis
All macroscopic and histological disease scores, as well
as cytokine levels were expressed as mean + SD, with p
< 0.05 being considered significant using the Student’s
t-test (unpaired, two-tailed). Where indicated ANOVA
was performed with Tukey post-hoc testing.
Results
Epithelial cell specific expression of ILK is induced by pro-
inflammatory stimuli in a PI3-kinase and stress-activated
protein kinase-dependent manner
We first used an in vitro system to determine whether
ILK expression is modulated by inflammatory stimuli.
SW480 colonic cells were exposed to LPS, and after 24
h ILK protein was induced, along with an increase in
phosphorylation of Akt at ser473. Expression of Akt
itself did not change (Figure 1A). To confirm these find-
ings in vivo, colonic explants were exposed to DSS and
as seen in Figure 1B, this also led to an increase in
expression ILK protein expression. Histological exami-
nation of tissue sections demonstrated that increased
ILK expression occurred both in the cytoplasm and
nuclei of the epithelial cell compartment (Figure 1C).
ILK expression was regulated by phosphatidylinositol 3-
kinase, as both Ly294006 and wortmannin were capable
of downregulating its induction at the protein level
when HCT116 cells were stimulated with interleukin 1
beta (IL-1b, Figure 1D). Regulation of its induction
occurs transcriptionally, as the same inhibitors attenu-
ated the induction of ILK mRNA (Figure 1E). In order
to determine whether other pathways were also impli-
cated, we observed that both of the stress-activated pro-
tein kinase inhibitors SP600125 and SB203580 were also
capable of a similar downregulation (Figure 1F).
ILK regulates weight loss and inflammation in acute DSS-
induced colitis
Evidence that ILK is highly expressed in inflammation
at mucosal surfaces suggests it may be important in
modulating gut immunity. This notion is supported by
our previous observations in the colitis-associated can-
cer model [10], where ILK-ko mice had reduced
inflammation-induced tumors. Hence we initially
examined whether ILK-ko mice differed from their lit-
termate controls in a model of acute colitis. Wild type
and ILK-ko mice were treated with 3.5% DSS and at
the end of 7 days (Figure 2A) there was a clear differ-
ence in the degree of weight loss observed in the ILK-
ko mice as compared with the wild-type group. By the
end of the second week these mice have recovered
from the acute insult and hence the difference is no
longer apparent. Histological examination confirmed
t h ew e i g h tl o s sd a t as i n c et h e r ew a sas i g n i f i c a n t
attenuation of the inflammatory response in the ILK-
ko mice (Figure 2B).
ILK regulates the capacity of epithelial cells to produce
CCL2 in vitro
Because of the reduced inflammatory cell infiltrate in
the ILK-ko mice, we postulated that ILK regulates the
ability of epithelial cells to express pro-inflammatory
mediators. Hence we investigated the ability of si-RNA
mediated knockdown of ILK to affect the expression of
inflammatory-cytokine induced production of chemo-
k i n e s .A st h ed a t ai nF i g u r e3i n d i c a t e ,e x p o s u r eo f
HCT116 cells to IL-1b induces expression of IL-8
(CXCL8), Rantes (CCL5) and MCP1 (CCL2), but not
MIG (CXCL9). Predictably, IL-1b also induces both
IBa and i-NOS. ILK knockdown had no effect on
either IL-1b-induced CXCL8 or CCL5 expression but
significantly inhibited the expression of CCL2. These
data were confirmed not only by si-RNA to knockdown
ILK and performing Q-PCR for CCL2, but also using a
specific inhibitor of ILK signaling, QLT0267 [14], both
of which resulted in reduced expression of CCL2 mes-
sage (Figure 3B). We also investigated another unrelated
si-RNA to knockdown ILK with similar effects on CCL2
expression (data not shown). ELISA further corrobo-
rated these results using the ILK inhibitor to detect IL-
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Figure 1 ILK is induced by pro-inflammatory stimuli. A. Colonic SW480 cells were stimulated with 1 ug/ml LPS for 24 h, and after harvesting
the cells, western immunoblotting was performed. Membranes were probed with antibodies for ILK, ser473Akt, Akt and beta-actin. ILK protein
induction is accompanied by an increase in the phosphorylation of Akt at ser473, but not the protein level of this kinase. The beta-actin is
shown as an internal control. B. This shows the response of a murine colonic explant to exposure with 2.5% DSS for 48 h. There is an increase in
the expression of ILK. The lower panel shows equivalent levels of beta-actin. C. Colons of control and DSS treated mice (48 h) were probed with
a polyclonal antibody to ILK. Besides an increase in the intensity of the signal generally, more than 50% of the epithelial cell nuclei stain
positively for ILK. D and E. Colonic HCT116 cells were stimulated with 5 ng/ml IL-1b for 4 h. Protein was obtained by lysing cells in
homogenization buffer and western blotting performed for ILK expression (D). Alternatively, RNA was obtained by Trizol and used for cDNA
synthesis; semi-quantitative RT-PCR for ILK was then performed using the primers indicated in materials and methods. Wortmannin and
Ly294002 were both capable of inhibiting the IL-1b-induced ILK protein and mRNA. The b-actin signal is shown as the internal control. F. The
experiment was repeated as in D with the addition of inhibitors of the MAPK pathway. Specifically PD98059, SP600125 and SB203580 were used
to inhibit the p42/44 ERK, P54/45 JNK and p38SAPKs respectively, and GAPDH used as the loading control. Data are representative of 3
independent experiments for each panel.
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sure to QLT0267 there was a significant (> 70%) reduc-
tion in IL-1b-induced CCL2. These findings indicate
that ILK is potentially capable of regulating epithelial
cell function by modulating the expression of a well-
described immune cell chemoattractant.
Expression of ILK in epithelial cells influences chronic gut
inflammation and production of CCL2 in vivo
We next investigated the impact of loss of ILK in
epithelial cells in a model of chronic colitis, as this is
considered to be more representative of human IBD. In
this model, mice were treated with 3 cycles of 2.5% DSS
for 5 days followed by 7 days without DSS treatment.
As the weight chart indicates (Figure 4A), with each
successive round of DSS there is a notable increasing
separation between ILK-ko mice and wild-type mice.
Specifically, after 36 days the amount of weight loss in
the ILK-ko mice was significantly less than that of their
wild-type counterparts. When the animals were sacri-
ficed we observed reduced macroscopic disease scores
in the ILK-ko group. These data were confirmed upon
examination of histological sections where ILK-ko mice
had significantly reduced inflammation and mucosal
damage (Figure 4B, C). Based on our finding that ILK
regulates expression of CCL2, we also measured expres-
sion of CCL2 mRNA and confirmed significantly
reduced expression in the ILK-ko mice (Figure 4D, E).
WT + 3.5% DSS    KO + 3.5% DSS
80
85
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95
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1       2       3       4               1       2       3       4
Group
Day 7                                   Day  15
110
P<0.05 A
B
P<0.01
Figure 2 Epithelial ILK provides a pro-inflammatory stimulus in acute colitis. A. Acute colitis was induced in mice using 3.5% DSS in the
drinking water. Mice were weighed daily, and the results after 7 days of DSS treatment, and following a further 8 days off DSS are shown. The
weights expressed as the percentage of original (mean ± SEM) are shown (1 = WT control, 2 = WT+DSS, 3 = ILK-ko (C), 4 = ILK-ko + DSS). There
is a significant attenuation of the normally observed weight loss in the ILK-ko mice at day 7 (p < 0.05, ANOVA, Tukey post-test). B. Representative
histological slides for each of the DSS treated groups are shown. The inflammatory infiltrate, surface epithelial disruption and edema are reduced
in the ILK-ko animals. There was a significant reduction in the inflammatory scores in the ILK-ko mice (n = 6 per group).
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Figure 3 ILK regulates CCL2 expression. A. Si-RNA was used to knockdown ILK and a scrambled oligonucleotide was used as a control. RNA
was extracted from HCT116 cells after 4 h of stimulation with IL-1b and reverse transcribed to make cDNA. This was used to determine the
message of the molecules shown using RT-PCR. CCL2 induction in response to the cytokine IL-1b was the only molecule whose expression was
blocked by si-RNA knockdown of ILK (see CCL2 panel, lane 4). This result was reproduced on 2 further occasions. B. The experiment was
repeated as in A except Q-PCR used to determine the expression of CCL2, either following si-RNA knockdown of ILK (left panel) or using the
QLT0267 inhibitor (right panel). C. HCT116 cells were pretreated with the specific ILK inhibitor QLT0267 for 1 hour before being stimulated with
IL-1b for the times indicated. CCL2 concentrations were determined in the culture supernatent using ELISA. The data are representative of two
separate experiments, each performed in triplicate (*p < 0.01).
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Figure 4 ILK regulates wasting disease and CCL2 expression in chronic colitis. A. Chronic DSS (2.5%) colitis was induced in 6 animals per
group using 3 rounds of 2.5% DSS in the drinking water. Animal weights were monitored and the data in A show that there was a significant
attenuation of the weight loss in the ILK-ko animals (squares), compared with the wild-type group (diamonds), (*p < 0.05). B. Assessment of
microscopic damage in these mice indicated a significant reduction in the ILK-ko mice (*p < 0.05). Representative histology is shown in C, where
an obvious loss of crypts, mucosal edema and inflammatory infiltrate are shown in the control sample. D. Total RNA was extracted from sections
of distal colon and reverse transcribed to make cDNA. This was used to determine the message levels of CCL2 using semi-quantitative RT-PCR.
As can be seen from this figure, CCL2 induction was significantly (*p < 0.05) reduced in the ILK-ko animals (the barchart E shows the message
levels corrected for b-actin, and are for the entire sets of 6 mice per treatment group). F. Distal colonic lysates were obtained using
homogenization buffer and then used to determine CCL2 levels by ELISA. The data are for 6 mice per group and show a reduction in levels of
CCL2 in the ILK-ko mice (**p < 0.01).
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CCL2 further confirmed these data (Figure 4F). Collec-
tively these data indicate that ILK normally promotes
intestinal inflammation, and that ILK-mediated regula-
tion of CCL2 production by epithelial cells may be
involved in this response.
Interconnection between ILK and fibronectin
CCL2 is a chemokine with a role in mediating fibrosis in
several systems, including the colon [15]. Intriguingly,
one of the interesting facets of ILK function is its capacity
to affect modulation of the extracellular matrix compo-
nent, fibronectin [16]. Since fibronectin is associated with
colitis and its expression levels undergo biphasic modula-
tion during induction of inflammation and during healing
[17], we speculated that loss of ILK in epithelial cells may
also have an impact on this protein. We initially asked
whether fibronectin is capable of regulating CCL2
expression by cultured epithelial cells. By plating cells on
tissue culture plates coated with increasing levels of
fibronectin we observed that there was an increase in the
amount of CCL2 detected in the medium by ELISA (Fig-
ure 5A). We also wanted to determine whether fibronec-
tin regulates the expression of its receptor (a5) and ILK.
Using the same in vitro system we found that fibronectin
stimulated a dose-dependenti n c r e a s ei ne x p r e s s i o no f
ILK and a5, peaking at 20 ug/ml (Figure 5B). Next, using
immunohistochemistry we observed that there is an
impressive reduction in fibronectin expression in the
ILK-ko mice in comparison with the wild-type mice (Fig-
ure 5C). We also determined that QLT0267 was capable
of preventing the fibronectin-mediated expression of a5
integrin (Figure 5D). Collectively, these data indicate the
existence of a bidirectional pathway whereby an ILK-
dependent mechanism is capable of regulating fibronec-
tin expression levels in the ECM, which is itself capable
of regulation ILK and its receptor a5 integrin, as well as
CCL2, by epithelial cells.
Expression of ILK in epithelial cells affects the infiltrating
T cell profile
We next investigated whether the development of T cell
responses was altered in ILK-ko mice. First, we analyzed
production of pro-inflammatory cytokines in the colonic
homogenates of the chronic DSS-induced colitis mice,
and found that ILK-ko mice had significant reductions
(up to 50%) in their levels of TNF-a,I F N - g and IL-
12p40 (Figure 6A). To specifically address the cytokine
profiles within the T cell compartment, mesenteric
lymph nodes were collected and intracellular staining
was performed on CD4+ T cells. As shown in Figure
6B, the data indicate a significant reduction in the intra-
cellular staining for IFNg,i nI L K - k om i c e( F i g u r e6 B ,
right panel), confirming an attenuated Th1 response.
Foxp3
+ Tregs are critical regulators of the intestinal
immunity [18]. Based on the reduction in IFN-g-producing
T cells, were hypothesized that there may be a correspond-
ing increase in Tregs. Indeed we found that the proportion
of Tregs was significantly increased in mesenteric lymph
nodes (Figure 6B, left panel). Based on these ex vivo
results, we next used immunohistochemistry to examine
the ratio of FoxP3 positive cells to total CD3 positive cells
in mice affected with chronic colitis. These data confirmed
that ILK-ko mice have a proportionately increased number
of Tregs infiltrating their intestinal mucosa (Figure 6C, D).
To determine the effect on Th17 cells, which are also criti-
cal determinants of colonic inflammation, immunofluores-
cence was performed. As the data indicate (Figure 6E and
6F) there is a significant reduction in the numbers of IL-
17A positive T cells within the ILK-ko mice.
Fibronectin is capable of regulating the development of T
regulatory cells
Based on our findings that ILK-ko mice have reduced
fibronectin and an increase in mucosal Tregs, and
recent evidence that Treg function can be regulated by
components of the extracellular matrix [19], we specu-
lated that these two observations may be linked. To test
whether the levels of fibronectin may directly affect
Treg development, we isolated CD4
+CD25
- T cells and
stimulated them under Treg-inducing conditions (TGF-
b and IL-2) in the absence or presence of increasing
amounts of fibronectin. Remarkably, we found that
fibronectin directly inhibits the development of Foxp3+
Tregs in a dose-dependent manner (Figure 7). These
data not only reveal an inverse link between the levels
of a major ECM component, fibronectin, and the differ-
entiation of Tregs, but they also provide a possible
mechanistic basis for the resistance of ILK-ko mice to
colitis.
Discussion
This work shows for the first time that the epithelial
expression of ILK, a molecule with a critical role in
bidirectional cellular signaling, impacts significantly on
mucosal immunity. ILK-ko mice consistently exhibited
less wasting disease in response to DSS-induced colitis,
had reduced macroscopic and histological scores of dis-
ease, and reduced pro-inflammatory cytokine produc-
tion. Not only was there a reduction in the levels of
colonic tissue cytokines in the ILK-ko mice, but also a
consistent reduction in the numbers of IFNg staining
cells in the MLN (and splenic) lymphocytes. These data
demonstrate that ILK normally functions to promote
pro-inflammatory effects on epithelial cells, at least in
part, via stimulating expression of CCL2 and fibronectin
expression, the latter of which acts on T cells to sup-
press the development of Tregs. Knowledge that Treg
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Figure 5 Fibronectin regulates CCL2, ILK and a5 integrin. HCT116 cells were plated on tissue culture plates coated with increasing levels of
fibronectin for 4 h. In A, the CCL2 levels were measured in the medium using ELISA. In B, the cells were subsequently lysed and equivalent
amounts of protein resolved using SDS page. After transfer the membranes were probed with the antibodies indicated. The data indicate
increased ILK and a5 integrin expression with increasing fibronectin exposure, peaking at 20 ug/ml. C. Immunohistochemistry was performed on
colonic sections using a fibronectin antibody on 3 different mice in each group. There is a clear reduction in fibronectin expression in the ILK
knockout mice (a representative slide is shown). D. HCT116 cells were exposed to the doses of fibronectin indicated and the QLT 0267
compound added at the start of the experiment. The cell lysates were then resolved using SDS-PAGE and probed with either the a5 integrin or
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Figure 6 Epithelial ILK regulates tissue expression of inflammatory cytokines. A. Interferon gamma, tumor necrosis factor alpha and
interleukin-12p40 cytokine levels were determined in colonic homogenates from 6 ILK-knockout animals and 6 wild-type controls (**p < 0.01). B.
Lymphocytes were obtained from mesenteric lymph nodes of wild-type and ILK-ko mice. Intracellular staining for FoxP3 and IFNg was performed
as described in materials and methods. After stimulation with PMA (25 ng/ml) and ionomycin (1 mg/ml) for 6 h, cells were fixed and
permeabilized. Then they were stained with the indicated antibodies and read on a BD FACS Canto. The data are from 6 ILK-ko and 6 wild-type
mice (*p < 0.05). C. Tissue sections were obtained from control and ILK-ko mice at the end of 3 rounds of DSS treatment, and processed for
immunohistochemistry. Using anti-CD3 and anti-FoxP3 antibodies, the number of positively staining cells were counted in 3 fields from 6
separate animals, in each group. The ratios obtained are shown in D (*p < 0.05). E. IL-17A staining was performed using immunofluorescence as
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vides a new paradigm in mucosal immunity and offers
mechanistic insight into why ILK-ko mice are resistant
to colitis.
We found that ILK regulates the expression of the
chemokine CCL2, both in vitro using an epithelial cell
line and possibly in vivo in colitic mice. This is impor-
tant not only because this chemokine is upregulated in
human IBD, with increased CCL2 levels having been
reported in the mucosa of IBD patients as determined
by immunohistochemistry and ELISA [20] but also,
because mice with either this chemokine genetically
deleted [21], or with its receptor (CCR2) deleted [22]
are protected from developing experimental colitis. The
net result of reduced CCL2 expression would be a
reduction in the influx of monocytes and lymphocytes,
leading to reduced inflammation in comparison to wild-
type mice. Of especial interest is the recent description
of an MCP-1 (CCL2) polymorphism that is associated
with Crohn’s disease [23], which may have implications
for disease pathogenesis.
Fibronectin is a large (250 kDa) molecular weight gly-
coprotein present in various tissue compartments, with
defined roles in cell adhesion, migration and prolifera-
tion. It exists as a dimer with each monomer con-
structed of repeating type I, II and III protein domains.
Alternative splicing at extra domains A and B as well as
at a connecting segment III leads to the occurrence of
over 20 different forms [24]. Previously it has been
shown that there is enhanced expression of fibronectin
in inflamed ulcerative colitis mucosa and in fibrotic
Crohn’s disease, but a reduced expression in inflamed
Crohn’s disease mucosa [25]. Interestingly, it was vir-
tually absent in intestinal fistulae from the latter popula-
tion [26]. It is known that ILK regulates the epithelial
expression of fibronectin, which is an important compo-
nent of the extracellular matrix, both by means of over-
expression and also gene knockdown studies [16,27].
A
B
Figure 7 Fibronectin regulates Treg differentiation. T lymphocytes (CD4+CD25-) were obtained from the mesenteric lymph nodes of mice
and exposed to plate bound anti-CD3 (10 mg/ml) and fibronectin, as well as soluble anti-CD28 (1 mg/ml), rIL-2 (100 u/ml) and TGFb (10 ng/ml)
as described in materials and methods. After 24 h the proportion of FoxP3+ cells were determined using FACS analysis. In A, i: representative
neutral, 1000 ng/ml fibronectin; ii: iTreg, 0 ng/ml fibronectin; iii: iTreg, 125 ng/ml fibronectin; iv: iTreg, 1000 ng/ml fibronectin. The barchart in B
represents the overall dose-response relationship, performed in triplicate and repeated twice. (*p < 0.05, **p < 0.01, using ANOVA).
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both the acute and healing phases of colitis [17]. We
have added to this by demonstrating that reduced
inflammation in the ILK-ko mice is attended by a reduc-
tion in levels of fibronectin expression. Because fibro-
nectin may mediate leucocyte binding [28], as these
cells traverse the extracellular matrix, part of the expla-
nation for reduced inflammation is simply that there are
fewer lymphocytes present to mediate tissue damage. As
many different cells are able to synthesize fibronectin
we can conclude that at least a part of this is due to its
reduced epithelial expression in ILK-ko mice. Our
observation that ILK, CCL2 and a5 integrin are induced
in response to fibronectin exposure, indicates an impor-
tant connection between these molecules, possibly
through a positive feedback loop.
Reconciling observations in chronic intestinal inflam-
mation, where CCL2 is increased in both UC and CD,
and changes in fibronectin expression, which appears to
only undergo an increase in UC (and fibrotic Crohn’s
disease), is not straightforward. Furthermore, the DSS-
induced colitis model utilized in this study is not one
where fibrosis is generally recognized to occur. This
suggests that another non-fibrosis associated, ILK-
CCL2-fibronectin pathway exists in early inflammation,
and that interference with any of these three compo-
nents is capable of attenuating the inflammatory
response. It is quite likely that alternative or additional
mechanism(s) operate(s) to effect inflammation in
Crohn’s disease, and consequently changes in fibronec-
tin expression are not observed. Future work will
address the role of ILK on other components of the
extracellular matrix that undergo changes in IBD.
Whilst changes in CCL2 and fibronectin may offer
plausible explanations for the reduction in inflamma-
tion seen in the ILK-ko mice, we were keen to investi-
gate potential additional immune mechanisms. The
reduction in the level of gamma-interferon indicates a
reduction in the Th1 response, and this observation
was seen in tissue homogenates, as well as in CD4(+)
cells harvested from the mesenteric lymph nodes. We
next turned to T regulatory cells, which are known to
have a fundamental role in regulation of mucosal
immunity [18]. Indeed, we found that protection of
ILK-ko mice from colitis correlated with a relative
increase in Foxp3+ Tregs in both the colon and in
mesenteric lymph nodes. Peripheral Treg development
in the gut can be driven by many different tolerogenic
s i g n a l ss u c ha sT G F - b, retinoic acid and IL-10. We
found that under the influence of TGF-b,f i b r o n e c t i n
directly inhibited the development of Foxp3+ cells, for
the first time providing a link between this and the
development of immune tolerance. This finding com-
plements recent data showing that another ECM
protein, high molecular weight hyaluronan, the ligand
for CD44, can promote the expression of FoxP3 [19],
further supporting the notion that the integrity of the
tissue matrix has a direct role in directing mucosal
immune responses. Moreover, the direct effects of
fibronectin on Treg development provide a mechanism
by which the loss of ILK in epithelial cells could lead
to a reduced susceptibility to colitis. Future research
will be required to define how this novel aspect of
Treg development is regulated at the molecular level.
There is considerable support for the involvement of
another T cell population in the pathogenesis of IBD,
specifically the Th17 cell [29]. In contrast to Th1
(requiring IFNg, and IL-12), Th2 (requiring IL-4) and
Treg (requiring TGFb and IL-2) cells, this particular cell
is dependent upon TGFb, IL-6 and IL-23 for its differ-
entiation [30]. It produces a different set of cytokines
that include IL-17, IL-22 and TNFa, and is character-
ized by the expression of the transcription factor RORgt.
An inverse relationship between a genetic polymorphism
of its surface IL-23 receptor (IL-23R) and Crohn’sd i s -
ease has been described [31]. Recent work indicates
some degree of T cell plasticity in that T cells that
express both IL-17 and RORgt have been described [32].
Our work indicates that the increased FoxP3+ cell
population in the ILK-ko mice is associated with a con-
comitant reduction in the IL-17+ cell population, in
response to induction of chronic colitis. The presence of
a smaller population of dual IL-17+/FoxP3+ cells cannot
be excluded. Furthermore we do not observe any com-
parable change in the Th17 cell fraction (as compared
to Tregs) upon plating onto fibronectin coated plates,
indicating a specific effect for Treg generation.
Conclusion
Our work provides the first striking example of an
intestinal epithelial cell molecule ILK, capable of influ-
encing the surrounding inflammatory milieu (through
CCL2), as well as the ECM (through fibronectin), which
in turn may impact on the mucosal inflammatory
response (via Th1, Th17 and Treg cells). We therefore
conclude that modulation of ILK signaling may have an
impact on human IBD, and that this merits attention.
Abbreviations
ILK: integrin-linked kinase; ILK-ko: ILK-intestinal epithelial cell knockout; CCL2:
chemokine (C-C motif) ligand 2.
Acknowledgements
This study was supported in part by funding from the Canadian Society of
Intestinal Research, and BS is supported by a VCHRI In-it-for life clinician-
scientist award.
Author details
1Department of Medicine, The Jack Bell Research Centre, 2660 Oak Street,
Vancouver, British Columbia, V6H 3Z6, Canada.
2Department of Surgery, The
Assi et al. BMC Immunology 2011, 12:42
http://www.biomedcentral.com/1471-2172/12/42
Page 13 of 14Jack Bell Research Centre, 2660 Oak Street, Vancouver, British Columbia,V6H
3Z6, Canada.
3British Columbia Cancer Research Centre, 10-110 675 West
10th Avenue, Vancouver, British Columbia, V5Z 1L3, Canada.
4Department of
Anatomical Pathology, The Jack Bell Research Centre, 2660 Oak Street,
Vancouver, British Columbia, V6H 3Z6, Canada.
Authors’ contributions
KA and SP performed the experimental work; DO provided input into
interpretation of pathology; SD provided essential reagents; ML provided
input into experimental design and edited the manuscript; BS was
responsible for conception and design, as well as writing the first and final
versions of the manuscript. All authors have read and approve of the final
version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 18 April 2011 Accepted: 1 August 2011
Published: 1 August 2011
References
1. Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory
bowel disease. Nature 2007, 448:427-34.
2. Cho JH: The genetics and immunopathogenesis of inflammatory bowel
disease. Nat Rev Immunol 2008, 8:458-66.
3. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T,
DeWoody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric
monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s
disease. Crohn’s Disease cA2 Study Group. N Engl J Med 1997,
337:1029-35.
4. Baumgart DC, Sandborn WJ: Inflammatory bowel disease: clinical aspects
and established and evolving therapies. Lancet 2007, 369:1641-57.
5. McDonald PC, Fielding AB, Dedhar S: Integrin-linked kinase - essential
roles in physiology and cancer biology. J Cell Sci 2008, 121:3121-32.
6. Hannigan G, Troussard AA, Dedhar S: Integrin-linked kinase: a cancer
therapeutic target unique among its ILK. Nat Rev Cancer 2005, 5:51-63.
7. Fukuda T, Chen K, Shi X, Wu C: PINCH-1 is an obligate partner of integrin-
linked kinase (ILK) functioning in cell shape modulation, motility, and
survival. J Biol Chem 2003, 278:51324-33.
8. McDonald PC, Oloumi A, Mills J, Dobreva I, Maidan M, Gray V, Wederell ED,
Bally MB, Foster LJ, Dedhar S: Rictor and integrin-linked kinase interact
and regulate Akt phosphorylation and cancer cell survival. Cancer Res
2008, 68:1618-24.
9. Liu E, Sinha S, Williams C, Cyrille M, Heller E, Snapper SB, Georgopoulos K,
St-Arnaud R, Force T, Dedhar S, et al: Targeted deletion of integrin-linked
kinase reveals a role in T-cell chemotaxis and survival. Mol Cell Biol 2005,
25:11145-55.
10. Assi K, Mills J, Owen D, Ong C, St Arnaud R, Dedhar S, Salh B: Integrin-
linked kinase regulates cell proliferation and tumour growth in murine
colitis-associated carcinogenesis. Gut 2008, 57:931-40.
11. Elson CO, Sartor RB, Tennyson GS, Riddell RH: Experimental models of
inflammatory bowel disease. Gastroenterology 1995, 109:1344-67.
12. Assi K, Pillai R, Gomez-Munoz A, Owen D, Salh B: The specific JNK inhibitor
SP600125 targets tumour necrosis factor-alpha production and epithelial
cell apoptosis in acute murine colitis. Immunology 2006, 118:112-21.
13. Troussard AA, Mawji NM, Ong C, Mui A, St-Arnaud R, Dedhar S: Conditional
knock-out of integrin-linked kinase demonstrates an essential role in
protein kinase B/Akt activation. J Biol Chem 2003, 278:22374-8.
14. Oloumi A, Syam S, Dedhar S: Modulation of Wnt3a-mediated nuclear
beta-catenin accumulation and activation by integrin-linked kinase in
mammalian cells. Oncogene 2006, 25:7747-57.
15. Motomura Y, Khan WI, El-Sharkawy RT, Verma-Gandhu M, Verdu EF,
Gauldie J, Collins SM: Induction of a fibrogenic response in mouse colon
by overexpression of monocyte chemoattractant protein 1. Gut 2006,
55:662-70.
16. Wu C, Keightley SY, Leung-Hagesteijn C, Radeva G, Coppolino M,
Goicoechea S, McDonald JA, Dedhar S: Integrin-linked protein kinase
regulates fibronectin matrix assembly, E-cadherin expression, and
tumorigenicity. J Biol Chem 1998, 273:528-36.
17. Kolachala VL, Bajaj R, Wang L, Yan Y, Ritzenthaler JD, Gewirtz AT, Roman J,
Merlin D, Sitaraman SV: Epithelial-derived fibronectin expression,
signaling, and function in intestinal inflammation. J Biol Chem 2007,
282:32965-73.
18. Izcue A, Coombes JL, Powrie F: Regulatory lymphocytes and intestinal
inflammation. Annu Rev Immunol 2009, 27:313-38.
19. Bollyky PL, Falk BA, Long SA, Preisinger A, Braun KR, Wu RP, Evanko SP,
Buckner JH, Wight TN, Nepom GT: CD44 costimulation promotes FoxP3+
regulatory T cell persistence and function via production of IL-2, IL-10,
and TGF-beta. J Immunol 2009, 183:2232-41.
20. Banks C, Bateman A, Payne R, Johnson P, Sheron N: Chemokine expression
in IBD. Mucosal chemokine expression is unselectively increased in both
ulcerative colitis and Crohn’s disease. J Pathol 2003, 199:28-35.
21. Khan WI, Motomura Y, Wang H, El-Sharkawy RT, Verdu EF, Verma-
Gandhu M, Rollins BJ, Collins SM: Critical role of MCP-1 in the
pathogenesis of experimental colitis in the context of immune and
enterochromaffin cells. Am J Physiol Gastrointest Liver Physiol 2006, 291:
G803-11.
22. Andres PG, Beck PL, Mizoguchi E, Mizoguchi A, Bhan AK, Dawson T,
Kuziel WA, Maeda N, MacDermott RP, Podolsky DK, et al: Mice with a
selective deletion of the CC chemokine receptors 5 or 2 are protected
from dextran sodium sulfate-mediated colitis: lack of CC chemokine
receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-
type immune response in the intestine. J Immunol 2000, 164:6303-12.
23. Palmieri O, Latiano A, Salvatori E, Valvano MR, Bossa F, Latiano T,
Corritore G, di Mauro L, Andriulli A, Annesec V: The -A2518G
polymorphism of monocyte chemoattractant protein-1 is associated
with Crohn’s disease. Am J Gastroenterol 105:1586-94.
24. Hynes RO, George EL, Georges EN, Guan JL, Rayburn H, Yang JT: Toward a
genetic analysis of cell-matrix adhesion. Cold Spring Harb Symp Quant Biol
1992, 57:249-58.
25. Brenmoehl J, Lang M, Hausmann M, Leeb SN, Falk W, Scholmerich J,
Goke M, Rogler G: Evidence for a differential expression of fibronectin
splice forms ED-A and ED-B in Crohn’s disease (CD) mucosa. Int J
Colorectal Dis 2007, 22:611-23.
26. Bataille F, Rohrmeier C, Bates R, Weber A, Rieder F, Brenmoehl J, Strauch U,
Farkas S, Furst A, Hofstadter F, et al: Evidence for a role of epithelial
mesenchymal transition during pathogenesis of fistulae in Crohn’s
disease. Inflamm Bowel Dis 2008, 14:1514-27.
27. Gagne D, Groulx JF, Benoit YD, Basora N, Herring E, Vachon PH, Beaulieu JF:
Integrin-linked kinase regulates migration and proliferation of human
intestinal cells under a fibronectin-dependent mechanism. J Cell Physiol
222:387-400.
28. Alon R, Cahalon L, Hershkoviz R, Elbaz D, Reizis B, Wallach D, Akiyama SK,
Yamada KM, Lider O: TNF-alpha binds to the N-terminal domain of
fibronectin and augments the beta 1-integrin-mediated adhesion of
CD4+ T lymphocytes to the glycoprotein. J Immunol 1994, 152:1304-13.
29. Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS, Cua DJ,
Powrie F, Cheever AW, Maloy KJ, et al: IL-23 plays a key role in
Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med 2006,
203:2485-94.
30. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM: Th17: an
effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006,
24:677-88.
31. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ,
Steinhart AH, Abraham C, Regueiro M, Griffiths A, et al: A genome-wide
association study identifies IL23R as an inflammatory bowel disease
gene. Science 2006, 314:1461-3.
32. Voo KS, Wang YH, Santori FR, Boggiano C, Arima K, Bover L, Hanabuchi S,
Khalili J, Marinova E, Zheng B, et al: Identification of IL-17-producing
FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci USA 2009,
106:4793-8.
doi:10.1186/1471-2172-12-42
Cite this article as: Assi et al.: Role of epithelial integrin-linked kinase in
promoting intestinal inflammation: effects on CCL2, fibronectin and the
T cell repertoire. BMC Immunology 2011 12:42.
Assi et al. BMC Immunology 2011, 12:42
http://www.biomedcentral.com/1471-2172/12/42
Page 14 of 14